Extent of disease: Patients with 10% or less vitiligo and particularly facial or limited lesions tend to benefit most from ...

I’ve been a vitiligo researcher for almost 20 years. While it affects people of all races and ethnicities equally, it’s more visible in people with darker skin tones. As a result, they may be more ...

For patients who had 12 months of continuous health care coverage before and after receiving a diagnosis of vitiligo, treatment rates were at suboptimal levels. Using data from the Merative MarketScan ...

There could be new hope for people afflicted with the skin-discoloring disease, vitiligo. A new treatment reportedly works great on mice with the malady, and it utilizes a natural substance produced ...

CARLSBAD, Calif. — When patients with vitiligo see Jessica Shiu, MD, PhD, for the first time, some mention that prior healthcare providers have told them that vitiligo is merely a cosmetic issue — ...

(RTTNews) - Royalty Pharma plc. (RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), have announced a funding agreement of up to $500 million to advance the ...

An estimated 1 in 100 people in the UK live with vitiligo, a long-term condition characterised by light patches of skin that have lost their pigmentation. Although not generally painful, its ...

Vitiligo is often misunderstood as merely a cosmetic issue, but for millions worldwide—including over a million in India—it’s a deeply personal and emotional struggle. Characterised by the loss of ...

Emily Kirkpatrick is a former associate style news editor at PEOPLE. She left PEOPLE in 2017. Vesnaandjic / Getty Images Vitiligo is a chronic disorder, often due to genetics or a change in the immune ...

More than 80,000 adults and teenagers across England suffering with a chronic skin condition could have their lives transformed after NICE today (Tuesday, 24 February) recommended the first licensed ...

A new cream offering hope to over 80,000 people in England living with vitiligo has been approved for NHS use. Ruxolitinib, sold under the brand name Opzelura, is the first licensed treatment to ...